Cellect Biotechnology Reports Third Quarter Financial and Operating Results; Recent Developments Position Company to Accelerate Progress in 2021
20 nov. 2020 08h00 HE
|
Cellect Biotechnology Ltd.
Promising Progress on Clinical Development Progress, Collaborations and Partnering Mutually Ended Discussion on Medical Cannabis Commercial and Merger Agreements TEL AVIV, Israel, Nov. 20, 2020 ...
Cellect Biotechnology Commences Collaboration with XNK Therapeutics to Advance Novel NK Cell-Based Therapies; Adds Another Partner for its Functional Cell Selection Technology
29 oct. 2020 08h00 HE
|
Cellect Biotechnology Ltd.
Tel Aviv, Israel , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Adding to a growing roster of partners, Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced that it has entered into and commenced a...
Cellect Biotechnology Initiates U.S. Clinical Trial of ApoGraft
22 oct. 2020 08h00 HE
|
Cellect Biotechnology Ltd.
Tel Aviv, Israel , Oct. 22, 2020 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology which enables the functional selection of cells facilitating...
Cellect Biotechnology to Present at the 2020 Cell & Gene Meeting on the Mesa
21 sept. 2020 08h30 HE
|
Cellect Biotechnology Ltd.
Management to Highlight Progress in Bone Marrow Transplant (BMT) and Chimeric Antigen Receptor T Cell (CAR T) Business Collaborations Tel Aviv, Israel, Sept. 21, 2020 (GLOBE NEWSWIRE) --...
Cellect Biotechnology Reports First Quarter 2020 Financial and Operating Results; Continues to Demonstrate Significant Progress Despite Adjusted Operations Due to COVID-19
21 mai 2020 16h00 HE
|
Cellect Biotechnology Ltd.
TEL AVIV, Israel, May 21, 2020 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology which enables the functional selection of stem cells, today...
Cellect Biotechnology Announces Exercise of Warrants for Cash Proceeds of Approximately $1.5 Million
12 mai 2020 08h48 HE
|
Cellect Biotechnology Ltd.
TEL AVIV, Israel, May 12, 2020 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today...
Cellect Biotechnology to Explore Strategic Alternatives to Maximize Shareholder Value
16 mai 2019 07h00 HE
|
Cellect Biotechnology Ltd.
Tel Aviv, Israel, May 16, 2019 (GLOBE NEWSWIRE) -- Following a review of its business, including the status of its clinical and development programs, resources and capabilities, Cellect...
Cellect Biotechnology Announces Receipt of Nasdaq Minimum Bid Price Notification
16 mai 2019 07h00 HE
|
Cellect Biotechnology Ltd.
Tel Aviv, Israel, May 16, 2019 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, announced today it has received notification...
Cellect Announces Closing of $6.5 Million Underwritten Public Offering
13 févr. 2019 17h00 HE
|
Cellect Biotechnology Ltd.
Tel Aviv, Israel, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, today announced the closing of its previously...
Cellect Announces Pricing of $6.5 Million Public Offering
08 févr. 2019 00h55 HE
|
Cellect Biotechnology Ltd.
Tel Aviv, Israel, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, today announced the pricing of an underwritten...